The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Reports Q4 revenue $64.3M, consensus $57.4M. “LifeMD (LFMD) had a great fourth quarter. We not only achieved record quarterly revenue and ...

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...

Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, ...

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 ...

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list ... Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...